Nasal Polyps Treatment Market Report 2026

The nasal polyps treatment market size has grown strongly in recent years. It will grow from $5.68 billion in 2025 to $6.22 billion in 2026 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to prevalence of chronic sinusitis, increasing allergy-associated nasal disorders, reliance on corticosteroid-based treatments, growing adoption of endoscopic sinus surgery, limited biologic treatment options.

The nasal polyps treatment market size is expected to see strong growth in the next few years. It will grow to $8.9 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to rising demand for targeted biologic drugs, increased r&d in nasal therapeutics, expansion of outpatient minimally invasive procedures, growing awareness of nasal polyp management, launch of innovative anti-inflammatory formulations. Major trends in the forecast period include increasing adoption of biologic therapies for chronic nasal polyps, growing demand for minimally invasive sinus procedures, rising use of combination therapy for persistent cases, expanding preference for nasal corticosteroid sprays, increasing clinical trials for novel anti-inflammatory drugs.

Rising healthcare expenditure is expected to drive growth in the nasal polyps treatment market. Healthcare expenditure encompasses the total financial resources spent by individuals, governments, and organizations on medical services, treatments, medications, and healthcare infrastructure. As healthcare budgets expand, more resources are available for the diagnosis, management, and treatment of nasal polyps, improving patient access to advanced therapies, innovative treatment options, and research and development. For instance, in April 2025, according to the Office for National Statistics, a UK-based statistics authority, the UK government’s net research and development expenditure rose to £17.4 billion (~US$21.8 billion) in 2023 from £16.1 billion (~US$20.1 billion) in 2022, an 8.2% increase. Therefore, rising healthcare expenditure is boosting the nasal polyps treatment market.

Major companies in the nasal polyps treatment market are focusing on obtaining FDA approvals to launch new therapies. FDA approvals involve regulatory evaluation and authorization of drugs, ensuring their safety and efficacy for public use. For instance, in September 2024, Regeneron Pharmaceuticals, Inc., a US-based biopharmaceutical company, and Sanofi SA, a France-based pharmaceutical company, announced FDA approval of Dupixent (dupilumab) as an add-on maintenance treatment for adolescents aged 12 to 17 with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). This marks the first and only biologic therapy specifically indicated for this age group, addressing the unmet medical needs of approximately 9,000 U.S. adolescents by improving symptoms, reducing nasal polyp recurrence, and enhancing quality of life.

In May 2025, Paratek Pharmaceuticals, a US-based specialty therapy provider, acquired Optinose, Inc., for approximately $330 million. Through this acquisition, Paratek aims to diversify its commercial portfolio beyond antibiotics and leverage its sales infrastructure to expand adoption of XHANCE among primary care and specialist providers. Optinose is a U.S.-based biopharmaceutical company that develops drug-device combination nasal therapies, including XHANCE (fluticasone propionate with a proprietary Exhalation Delivery System) for chronic rhinosinusitis.

Major companies operating in the nasal polyps treatment market are Sanofi SA, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Genentech Inc., Glenmark Pharmaceuticals Ltd., Lupin Limited, Novartis AG, Optinose US Inc., Pfizer Inc., Regeneron Pharmaceuticals Inc., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Zydus Cadila Ltd., Amgen Inc., Takeda Pharmaceutical Company Ltd., Eli Lilly and Company, Daiichi Sankyo Company Ltd., Shionogi Co Ltd, Astellas Pharma Inc., Allakos Inc, Lyra Therapeutics Inc.

North America was the largest region in the nasal polyps treatment market in 2025 Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nasal polyps treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nasal polyps treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased costs in the nasal polyps treatment market by raising prices for imported biologics, corticosteroids, and surgical equipment used in endoscopic sinus procedures. Pharmacological therapies and surgical segments are most affected, particularly in North America and Asia-Pacific where imports dominate. These price increases have put pressure on healthcare budgets. On the positive side, tariffs are supporting local pharmaceutical production and regional surgical device manufacturing.

The nasal polyps treatment market research report is one of a series of new reports that provides nasal polyps treatment market statistics, including nasal polyps treatment industry global market size, regional shares, competitors with a nasal polyps treatment market share, detailed nasal polyps treatment market segments, market trends and opportunities, and any further data you may need to thrive in the nasal polyps treatment industry. This nasal polyps treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nasal polyps are soft, painless, noncancerous growths that develop on the lining of the nasal passages or sinuses. They often hang like grapes or teardrops and are associated with conditions such as asthma, chronic infections, allergies, medication sensitivity, and other immune-related disorders.

The nasal polyps treatment market involves the sale of therapies and interventions by organizations, sole traders, and partnerships aimed at treating nasal polyps by shrinking or removing these growths. Treatments focus on reducing the size of polyps or repairing affected tissue to alleviate associated symptoms and improve nasal airflow.

The nasal polyps treatment market includes revenues earned by entities by nasal corticosteroids, oral and injectable corticosteroids, and other medications. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.